Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models. - Wikidata - wikimedia - TriplyDB

Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models.

Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models.

http://www.wikidata.org/entity/Q34103876

about

Nuclear FAK: a new mode of gene regulation from cellular adhesions FAK in cancer: mechanistic findings and clinical applications Evolving Therapies and FAK Inhibitors for the Treatment of Cancer Knock-in mutation reveals an essential role for focal adhesion kinase activity in blood vessel morphogenesis and cell motility-polarity but not cell proliferation.Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer FAK Inhibition disrupts a β5 integrin signaling axis controlling anchorage-independent ovarian carcinoma growth.Combined BRAF(V600E)- and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer.Fluorescent-tilmanocept for tumor margin analysis in the mouse model.Pyk2 promotes tumor progression in multiple myeloma p190RhoGEF (Rgnef) promotes colon carcinoma tumor progression via interaction with focal adhesion kinase.Understanding the roles of FAK in cancer: inhibitors, genetic models, and new insights A tumor-suppressing function in the epithelial adhesion protein Trask.FAK activity protects nucleostemin in facilitating breast cancer spheroid and tumor growth Pharmacokinetic analysis of the FAK scaffold inhibitor C4 in dogs Dietary fat increases solid tumor growth and metastasis of 4T1 murine mammary carcinoma cells and mortality in obesity-resistant BALB/c mice Prostaglandins in cancer cell adhesion, migration, and invasion Nuclear-localized focal adhesion kinase regulates inflammatory VCAM-1 expression.Kinases as targets for chemical modulators: Structural aspects and their role in spermatogenesis.Identification of new candidate therapeutic target genes in triple-negative breast cancer Anti-metastatic action of FAK inhibitor OXA-11 in combination with VEGFR-2 signaling blockade in pancreatic neuroendocrine tumors Focal adhesion kinase contributes to proliferative potential of ErbB2 mammary tumour cells but is dispensable for ErbB2 mammary tumour induction in vivo 3'3-Diindolylmethane inhibits migration, invasion and metastasis of hepatocellular carcinoma by suppressing FAK signaling.Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide.The effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cells Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression.pHocal adhesion kinase regulation is on a FERM foundation.A non-canonical role for Rgnef in promoting integrin-stimulated focal adhesion kinase activation.Inhibition of endothelial FAK activity prevents tumor metastasis by enhancing barrier function.Ambivalent role of pFAK-Y397 in serous ovarian cancer--a study of the OVCAD consortium.Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer.Focal adhesion kinase as a cancer therapy target.Influence of stress on extracellular matrix and integrin biology.Targeting FAK in human cancer: from finding to first clinical trials.RhoGEFs in cell motility: novel links between Rgnef and focal adhesion kinase.Focal adhesion kinase inhibitors in the treatment of metastatic cancer: a patent review.Pathobiology of pancreatic cancer: implications on therapy.Molecular Pathways: Endothelial Cell FAK-A Target for Cancer Treatment.Colorectal Cancer Metastases Settle in the Hepatic Microenvironment Through α5β1 Integrin.Emerging roles of focal adhesion kinase in cancer.FAK Expression, Not Kinase Activity, Is a Key Mediator of Thyroid Tumorigenesis and Protumorigenic Processes.

P2860

Q26864184-44D96DD1-3FE6-42CF-9D20-CF9FE307B2B7 Q27026533-7C65311B-EC2C-4BA2-BD6B-4140430912E6 Q28972291-6E4DDE71-8DBF-4DC6-96AB-48790F09E711 Q30495320-D4977C37-3C7A-4C5D-9E7D-884C421004F6 Q33787214-BD84CA5E-DEB5-4D0C-8900-354BC06CE92E Q34021043-78D49D12-8A4A-448C-BABA-0D36D45A2C36 Q34100838-3E9803F6-FFC3-4090-B98B-9D919AECDFEB Q34363958-05181786-22D5-4FD2-BC7B-766309ABF9E3 Q34398382-DE31DCCD-D871-4699-872E-E12C2CA02494 Q34721988-9987801B-70D7-4DEE-AC86-F835BC5FC1B8 Q35009792-07BD80D7-0514-4EBE-861E-52A107A5DD59 Q35250126-89B4C463-7EF2-40FC-BA6F-1512CEF72367 Q35532179-DB2775A3-A17F-4771-ADB8-69611FAC9F7F Q35582654-14E3AD70-5D80-4BC5-A710-DF65F6C1B19C Q35608714-0D9492DE-A4C4-4D0F-85F7-F207F6AE1ED2 Q35821653-36E72FC9-0B09-4207-8351-E6E30539A3A1 Q36062070-2831F2C0-BB4E-4C1C-893E-B6773DD04506 Q36088077-4E4ED655-5828-4A87-83D6-642B6BF40724 Q36153325-B563C736-FD6A-42EC-9B63-5713156224EF Q36296805-B66AA769-3125-44D2-9F6B-9168E6A762A8 Q36393238-74738B7C-D0D5-43E2-B27C-71834CB63751 Q36414292-EE5D429B-E10E-4F1C-8DF6-1683A3435D61 Q36604850-6BB06F66-6284-4A64-87D4-81BC81A69152 Q36725203-689EB2A5-C50D-45FC-BF7F-4C3F1A36E846 Q36754457-FA11467F-DC68-4D06-924B-7F123D4D9095 Q37180585-C79C0C35-427F-425B-B334-397536D2E79D Q37287392-20D47CB8-7CC7-4E42-8E9A-0075866C26BB Q37498587-EA4B4C10-4C84-42BB-BA8D-85D952A505F9 Q37720579-659F2783-18EA-4283-BB5F-4BF294B09DAA Q37750751-10D1BE5E-A91A-43D6-BE9C-DDAFD2724055 Q37826762-CA5BBDC9-BE95-4FE7-B706-466FACF47902 Q37845642-FB016786-3DEF-4667-BF39-BFAC8CF776A8 Q38175738-301DDC4D-BDD5-42D1-AC58-B765BD1E3237 Q38182132-2E777E1E-D795-454E-8DFA-E2B9F9A9B044 Q38239003-EC260DD2-E27B-4AE8-91FD-A67BA5877E3A Q38664687-0DC271D6-EAFE-4BBA-8370-D155E9D494A3 Q38854580-BF5E761C-5D9F-45DF-A54E-1E4451BED37D Q38889277-E8ACCCFA-C52B-402F-A1DB-31A9797E779C Q39611596-7AD0FF21-0C1D-481B-AB0E-DFF3400BEE0D Q39711361-589246C1-4A66-4E3E-8CDD-EE4FC253C46B

P2860

Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models.

http://www.wikidata.org/entity/Q34103876

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Oral delivery of PND-1186 FAK ...... stasis in pre-clinical models.

@ast

Oral delivery of PND-1186 FAK ...... stasis in pre-clinical models.

@en

Oral delivery of PND-1186 FAK ...... stasis in pre-clinical models.

@nl

type

label

Oral delivery of PND-1186 FAK ...... stasis in pre-clinical models.

@ast

Oral delivery of PND-1186 FAK ...... stasis in pre-clinical models.

@en

Oral delivery of PND-1186 FAK ...... stasis in pre-clinical models.

@nl

prefLabel

Oral delivery of PND-1186 FAK ...... stasis in pre-clinical models.

@ast

Oral delivery of PND-1186 FAK ...... stasis in pre-clinical models.

@en

Oral delivery of PND-1186 FAK ...... stasis in pre-clinical models.

@nl

P1433

Q34103876-FA54791B-3946-41BB-936B-DF0935F78DDF

P1476

Q34103876-6AFC4226-65B1-44AC-8370-3C4A983604C3

P2093

Q34103876-0B9D10E2-7F60-415A-9C32-6408A22084BA

Q34103876-18BD4477-BAE0-4DA1-ADEA-E362D402C0B9

Q34103876-1B4B2BC5-3031-4592-9A34-36B712D09AC6

Q34103876-4783D2EB-12AF-4E9E-B7CE-3482D0B59B5A

Q34103876-4E30AA9E-F8CE-4B10-8DA1-692D8FCED7DF

Q34103876-4E78DEAF-A260-44C4-AA15-5D153EB48910

Q34103876-57355FEA-44B2-436B-A2C1-FF28F9A4EEB0

Q34103876-594F0363-B4D3-4DBC-BE6E-E24C480796BC

Q34103876-A695E69A-2A11-41B4-A6F8-4B1F3E7125D9

Q34103876-B23CEFF7-A446-4055-BC72-A9767E59C002

P2860

Q34103876-00A1130C-E3D8-4D1D-829D-91B0D2CE10B0

Q34103876-072AA5FA-DDBF-43B0-926B-384211F5B147

Q34103876-0772645C-F8BB-40EC-85A3-F679FC8EDB17

Q34103876-0E227C2D-52CB-4014-8749-E9A7A06DBA59

Q34103876-153F64D0-9277-48DB-89CB-34AE6CB6C8C3

Q34103876-1A47B2CB-D109-4BB9-8769-667DD87C2812

Q34103876-1E12D65F-BA9B-47C3-9522-F621673040B7

Q34103876-1F0CBB5C-E78C-46F3-8276-BF7E61FAEA77

Q34103876-284A49FE-36D5-4CCA-84E8-5ACB731A7CD5

Q34103876-28CD2C3F-CEB4-4605-8D86-E1D86CD71F4A

P304

Q34103876-7D0B62EF-169C-4193-B405-46EF6E0A0A4B

P31

Q34103876-9CF43A48-F86C-4FBD-AF41-3CAF3A4D4196

P356

Q34103876-4610D056-84B3-437C-8EFF-CE61BDB71F5B

P433

Q34103876-D4DFCA91-8D7A-4D13-AC16-0A0524E6DC0E

P478

Q34103876-AB6EE9B9-86CB-4020-8A00-2351F163ED94

P577

Q34103876-A0E84211-1E66-4AA1-B993-1296D5A5A932

P5875

Q34103876-6C5DBB5D-14F3-4E91-926D-9C0B551285F1

P698

Q34103876-1156029B-1FD4-4896-A68C-8A93F67A0237

P932

Q34103876-E7C77981-1EC8-4B9A-8471-918A5F66C03A

P356

P1433

Cancer Biology and Therapy

P1476

Oral delivery of PND-1186 FAK ...... stasis in pre-clinical models.

@en

P2093

Alok Tomar

http://www.w3.org/2001/XMLSchema#string

Angelica Phillips

http://www.w3.org/2001/XMLSchema#string

Cheni Kwok

http://www.w3.org/2001/XMLSchema#string

Colin Walsh

http://www.w3.org/2001/XMLSchema#string

David D Schlaepfer

http://www.w3.org/2001/XMLSchema#string

Dwayne G Stupack

http://www.w3.org/2001/XMLSchema#string

Gerald McMahon

http://www.w3.org/2001/XMLSchema#string

Hong Luo

http://www.w3.org/2001/XMLSchema#string

Isabelle Tanjoni

http://www.w3.org/2001/XMLSchema#string

Ju-Ock Nam

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability

Integrin-regulated FAK-Src signaling in normal and cancer cells

Inflammation and cancer

Differential regulation of cell motility and invasion by FAK

Nontransgenic models of breast cancer

Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271

Signaling through focal adhesion kinase

Focal adhesion kinase: in command and control of cell motility

Breast cancer metastasis: markers and models

Differential requirement for focal adhesion kinase signaling in cancer progression in the transgenic adenocarcinoma of mouse prostate model

P304

778-790

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/CBT.9.10.11433

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2010-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

42109259

http://www.w3.org/2001/XMLSchema#string

P698

20234193

http://www.w3.org/2001/XMLSchema#string

P932

2933309

http://www.w3.org/2001/XMLSchema#string